Anti-inflammatory compositions and methods
First Claim
Patent Images
1. A therapeutic composition, comprising:
- at least one first agent configured to modulate the activity of one or more NF-κ
B molecules;
at least one second agent configured to modulate the activity of one or more Src family kinases; and
at least one pharmaceutically-acceptable carrier or excipient.
1 Assignment
0 Petitions
Accused Products
Abstract
Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.
64 Citations
204 Claims
-
1. A therapeutic composition, comprising:
-
at least one first agent configured to modulate the activity of one or more NF-κ
B molecules;at least one second agent configured to modulate the activity of one or more Src family kinases; and at least one pharmaceutically-acceptable carrier or excipient. - View Dependent Claims (9, 10, 14, 16, 17, 18, 23, 24, 26, 39, 43, 46)
-
-
2-8. -8. (canceled)
-
11-13. -13. (canceled)
-
15. (canceled)
-
19-22. -22. (canceled)
-
25. (canceled)
-
27-38. -38. (canceled)
-
40-42. -42. (canceled)
-
44-45. -45. (canceled)
-
47-56. -56. (canceled)
-
57. A method of modulating at least one immune response of one or more cells of a subject, comprising:
-
administering to a subject an effective amount of at least one therapeutic composition, including at least one first agent configured to modulate the activity of one or more NF-kB molecules; at least one second agent configured to modulate the activity of one or more Src family kinases; and at least one pharmaceutically-acceptable carrier or excipient. - View Dependent Claims (65, 69, 71, 72, 73, 74, 78, 79, 98, 101, 104, 109)
-
-
58-64. -64. (canceled)
-
66-68. -68. (canceled)
-
70. (canceled)
-
75-77. -77. (canceled)
-
80-97. -97. (canceled)
-
99-100. -100. (canceled)
-
102-103. -103. (canceled)
-
105-108. -108. (canceled)
-
110-124. -124. (canceled)
-
125. A method of modulating the activity of one or more NF-kB molecules and one or more Src family kinases in one or more cells of a subject, comprising:
-
administering to the subject an effective amount of at least one therapeutic composition, including at least one first agent configured to modulate the activity of one or more NF-kB molecules, at least one second agent configured to modulate the activity of one or more Src family kinases; and
at least one pharmaceutically-acceptable carrier or excipient. - View Dependent Claims (133, 134, 138, 140, 142, 147, 148, 150, 165, 169, 177)
-
-
126-132. -132. (canceled)
-
135-137. -137. (canceled)
-
139. (canceled)
-
141. (canceled)
-
143-146. -146. (canceled)
-
149. (canceled)
-
151-164. -164. (canceled)
-
166-168. -168. (canceled)
-
170-176. -176. (canceled)
-
178-192. -192. (canceled)
-
193. A method of treating a subject afflicted with or suspected of being afflicted with at least one inflammatory disease or condition, comprising:
-
administering to the subject an effective amount of at least one therapeutic composition, including at least one of disulfiram, ditiocarb, sulindac, sulfasalazine, or bortezomib, at least one of dasatinib, nilotinib, BMS-268770, UR-12947, aztreonam, MZ-338, riluzole, meloxicam, pramipexole, CBS-113-A, AZD0530, INNO-406, MK-0457, cediranib, sunitinib, bosutinib, axitinib, erlotinib, gefitinib, lapatinib, lestaurtinib, semaxanib, or imatinib; and
at least one pharmaceutically-acceptable carrier or excipient. - View Dependent Claims (194, 195, 197)
-
-
196. (canceled)
-
198. (canceled)
-
199. A method of treating a subject afflicted with or suspected of being afflicted with malaria, comprising:
-
administering to the subject an effective amount of at least one therapeutic composition, including at least one of disulfiram, ditiocarb, sulindac, sulfasalazine, or bortezomib; at least one of dasatinib, nilotinib, BMS-268770, UR-12947, aztreonam, MZ-338, riluzole, meloxicam, pramipexole, CBS-113-A, AZD0530, INNO-406, MK-0457, cediranib, sunitinib, bosutinib, axitinib, erlotinib, gefitinib, lapatinib, lestaurtinib, semaxanib, or imatinib; and
at least one pharmaceutically-acceptable carrier or excipient. - View Dependent Claims (200, 201, 203)
-
-
202. (canceled)
-
204. (canceled)
Specification